CBT
REGN icon

Crews Bank & Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Crews Bank & Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19
Closed -$9.97K – 651
2025
Q2 		$9.97K Hold
19
– – ﹤0.01% 521
2025
Q1 		$12.1K Hold
19
– – ﹤0.01% 494
2024
Q4 		$13.5K Buy
+19
New +$15.9K ﹤0.01% 482

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Crews Bank & Trust's REGN Position: Q3 2025 in Review

Crews Bank & Trust sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 19 shares — an estimated $9.97K sold.

Crews Bank & Trust first reported a position in REGN in Q4 2024 and held it in 3 quarters. The position peaked at $13.5K in Q4 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Crews Bank & Trust reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Crews Bank & Trust sold 19 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $9.97K.
  • Crews Bank & Trust first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Crews Bank & Trust's Regeneron Pharmaceuticals position peaked at $13.5K in Q4 2024.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Crews Bank & Trust's 13F filing for Q3 2025, filed 22 Oct 2025.